Strata Wealth Advisors LLC Raises Stake in Johnson & Johnson (NYSE:JNJ)

Strata Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 219.2% in the 1st quarter, HoldingsChannel.com reports. The fund owned 5,927 shares of the company’s stock after buying an additional 4,070 shares during the quarter. Strata Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $938,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the business. Norges Bank acquired a new stake in Johnson & Johnson during the fourth quarter worth about $4,071,642,000. Wellington Management Group LLP grew its stake in shares of Johnson & Johnson by 16.4% during the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after purchasing an additional 3,391,657 shares during the period. International Assets Investment Management LLC increased its holdings in shares of Johnson & Johnson by 7,875.8% during the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock valued at $327,647,000 after purchasing an additional 2,064,175 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $193,050,000. Finally, Global Assets Advisory LLC acquired a new stake in Johnson & Johnson during the first quarter valued at $170,372,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

JNJ opened at $146.42 on Tuesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The firm has a market capitalization of $352.39 billion, a PE ratio of 9.13, a PEG ratio of 2.43 and a beta of 0.52. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The firm’s 50-day moving average price is $148.14 and its 200 day moving average price is $154.05.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period in the previous year, the firm posted $2.68 EPS. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, sell-side analysts expect that Johnson & Johnson will post 10.62 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. Johnson & Johnson’s payout ratio is presently 30.92%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on JNJ. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Monday, June 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday. The Goldman Sachs Group started coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 target price on the stock. Finally, Bank of America cut their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $174.07.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.